305 related articles for article (PubMed ID: 24156324)
1. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
2. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
Sonpavde G; Sternberg CN; Rosenberg JE; Hahn NM; Galsky MD; Vogelzang NJ
Lancet Oncol; 2010 Sep; 11(9):861-70. PubMed ID: 20537950
[TBL] [Abstract][Full Text] [Related]
3. Targeted agents in second-line bladder cancer therapy.
Gerullis H; Otto T; Ecke TH
Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
[TBL] [Abstract][Full Text] [Related]
4. Second-line therapy in bladder cancer.
Bachner M; De Santis M
Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
[TBL] [Abstract][Full Text] [Related]
5. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T
Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839
[TBL] [Abstract][Full Text] [Related]
6. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
Gallagher DJ; Milowsky MI; Bajorin DF
Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
[TBL] [Abstract][Full Text] [Related]
7. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma.
McCaffrey JA; Herr HW
Surg Oncol Clin N Am; 1997 Oct; 6(4):667-81. PubMed ID: 9309087
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy for urothelial cancer of the bladder--update 2012].
Niegisch G; Lorch A; Albers P
Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic applications of the molecular events in clinical management of urothelial carcinoma of bladder.
Garg M
J Exp Ther Oncol; 2014; 10(4):301-16. PubMed ID: 25509986
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for urothelial carcinoma.
Gartrell BA; Sonpavde G
Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
[TBL] [Abstract][Full Text] [Related]
13. Update on chemotherapy for advanced bladder cancer.
Rosenberg JE; Carroll PR; Small EJ
J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
Buti S; Ciccarese C; Zanoni D; Santoni M; Modena A; Maines F; Gilli A; Bria E; Brunelli M; Rimanti A; Cascinu S; Ardizzoni A; Tortora G; Massari F
Future Oncol; 2015; 11(1):107-19. PubMed ID: 25572786
[TBL] [Abstract][Full Text] [Related]
16. Management of disseminated disease in the patient with bladder cancer.
Perry JJ; Muss HB
Urol Clin North Am; 1994 Nov; 21(4):661-72. PubMed ID: 7974898
[TBL] [Abstract][Full Text] [Related]
17. Systemic chemotherapy for advanced bladder cancer: update and controversies.
Garcia JA; Dreicer R
J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
[TBL] [Abstract][Full Text] [Related]
18. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of everolimus in metastatic urothelial cancer.
Smith AB; Pruthi RS
BJU Int; 2013 Aug; 112(4):427-8. PubMed ID: 23879903
[No Abstract] [Full Text] [Related]
[Next] [New Search]